Syngene International Limited — Updates, 23-04-2025: Press Release

Syngene International Limited has reported a strong performance for Q4 and the full year FY25. For the fourth quarter, revenue from operations increased 11% year-on-year, reaching Rs. 1,018 Cr, while for the full year, revenues rose 4% to Rs. 3,642 Cr. The Q4 operating EBITDA climbed 8% year-on-year, maintaining a solid EBITDA margin of 34%. The reported profit after tax for Q4 stood at Rs. 183 Cr, showing a slight decline from the previous year. Over the full year, profit after tax before exceptional items decreased 8% to Rs. 475 Cr.

The company also announced the acquisition of a biologics manufacturing facility in the US, enhancing its capabilities in the fast-growing biologics market and increasing total bioreactor capacity. Management indicated that despite market uncertainties, they expect to maintain business momentum, with revenue growth anticipated in the early teens for FY26. Key strategic investments and ongoing growth in research and development services position Syngene well for future opportunities in the sector, suggesting a positive outlook for investors.